”It’s probably the most important approval we have received in many years”
The recent FDA approval of diabetes drugs Tresiba and Ryzodeg means Novo Nordisk can eventually go on to become a market leader in the US, according to CSO Mads Krogsgaard Thomsen.
BY NIKLAS KRIGSLUND
“What do you think?”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Tresiba approval would mean massive boost to Novo share
For abonnenter
”Old” Novo drug to take center stage in Tresiba launch
For abonnenter
